Eli Lilly keeps close eye on Novo Holdings' planned billion-dollar Catalent transaction
Novo Nordisk’s major US rival, Eli Lilly, is watching closely from the sidelines following Monday’s announcement that Novo Holdings is on the verge of acquiring subcontractor and contract manufacturer Catalent.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly expects new drugs to drive 18% growth in 2024
For subscribers